Richard Shelby actually said...

Today's hearing will examine the difficult task of defining and regulating systemic risk.

Unfortunately, Dodd-Frank provides little guidance on exactly which firms should be designated for systemic risk regulation.

As research becomes more expensive and private capital dries up, I believe it's critical to ensure support for translational research.

It seems like that's an ideal opportunity for academia to team with industry to bring treatments to patients faster.